Also trades as: NBRV (NASDAQ) · $vol 0M
NBRVF Earnings
Nabriva Therapeutics plc
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: -0.0%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Next Earnings
2026-11-13
EPS Estimate
$-8.67
Range: $-8.67 - $-8.67
Revenue Estimate
$6M
1 analysts
Estimate vs Actual
Earnings Surprise History
Wall Street Forward Estimates
Quarterly
Annual
Estimate Revisions
Recent Revisions
| Date | Period | Fiscal Date | EPS Old | EPS New | Change | Rev Old | Rev New |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | quarter | 2027-06-30 | $-4.75 | $-4.75 | — | $9,575,000 | $10,099,000 |
| 2026-10-01 | quarter | 2028-12-30 | $-1.95 | $-2.30 | ▼ 0.35 | $18,400,000 | $17,400,000 |
| 2026-10-01 | quarter | 2028-03-30 | $-4.03 | $-4.03 | — | $9,843,500 | $10,675,000 |
| 2026-10-01 | quarter | 2027-12-30 | $-4.03 | $-5.00 | ▼ 0.97 | $10,675,000 | $8,530,000 |
| 2026-10-01 | quarter | 2029-03-30 | $-1.33 | $-1.95 | ▼ 0.62 | $22,074,000 | $18,400,000 |
| 2026-10-01 | quarter | 2026-09-30 | $-8.67 | $-16.75 | ▼ 8.08 | $5,985,667 | $2,250,000 |
| 2026-10-01 | quarter | 2027-03-30 | $-4.75 | $-5.50 | ▼ 0.75 | $10,099,000 | $8,895,000 |
| 2026-10-01 | quarter | 2026-12-30 | $-5.50 | $-8.67 | ▼ 3.17 | $8,895,000 | $5,985,667 |
| 2026-10-01 | quarter | 2028-09-30 | $-2.30 | $-3.37 | ▼ 1.07 | $17,400,000 | $12,900,000 |
| 2026-10-01 | quarter | 2028-06-30 | $-3.37 | $-4.03 | ▼ 0.66 | $12,900,000 | $9,843,500 |
| 2026-10-01 | quarter | 2029-06-30 | $-1.95 | $-1.33 | ▲ 0.62 | $18,400,000 | $22,074,000 |
| 2026-10-01 | quarter | 2027-09-30 | $-5.00 | $-4.75 | ▲ 0.25 | $8,530,000 | $9,575,000 |
| 2026-08-12 | annual | 2018-12-31 | $— | $-524.69 | ▼ 524.69 | $— | $9,518,631 |
| 2026-08-12 | annual | 2020-12-31 | $— | $-132.08 | ▼ 132.08 | $— | $4,113,667 |
| 2026-08-12 | annual | 2022-12-31 | $— | $-17.52 | ▼ 17.52 | $— | $36,207,500 |
Earnings Call Transcripts
No transcripts available.